November 24, 2014 | The Israeli biopharmaceutical company developing a universal influenza vaccine, BiondVax, is considering a Wall Street IPO, according to a “Globes” report. The company currently has a market cap of NIS 42 million (approx. $10.8 million) on the Tel Aviv Stock Exchange, which it hopes to maintain in a potential American offering. BiondVax’s universal flu vaccine, to treat a number of prominent flu strains, has already undergone a successful Phase II clinical trial and further trials will take place in 2015. BiondVax was founded in 2003 by its CEO Ron Babecoff.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Non-Profit Launches 10M Shekel Fund For Israeli Small Businesses
December 06, 2023

Amid War, Program Helps Open US Doors For 10 Israeli Startups
December 06, 2023

Israeli Data Privacy Startup Raises $30M in Wartime
December 05, 2023

Israel Awards ‘World’s First’ License For Drone Flights
December 05, 2023
Facebook comments